HIV studies

Vogue

VOGUE seeks to evaluate the efficacy, safety, and tolerability of using an oral once-daily 2-drug regimen compared to an oral once-daily 3-drug regimen as a first line regimen for the treatment of HIV-1 patients. Patients will be randomised to either: Dovato or Biktarvy 

VOGUE:Phase3b study comparing 2 oral regimens in naive adults with HIV - Health Research Authority (hra.nhs.uk) 

Principal investigator: Prof Alan Winston

FOST Switch

Evaluating efficacy and safety of switching a boosted protease inhibitor to fostemsavir in PLWH with limited therapeutic options

FOST Switch - Health Research Authority (hra.nhs.uk) 

Principal investigator: Prof Alan Winston

DORDOL

DORDOL aims to investigate the efficacy of switching patients on triple cART to dual cART; to reduce exposure to side effects whilst providing the same quality of care.

DORDOL - Health Research Authority (hra.nhs.uk)

The RIO trial

A randomised placebo controlled trial of ART plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) vs ART plus placebo in treated Primary HIV Infection on viral control off ART

The RIO Trial - Health Research Authority (hra.nhs.uk)

Principal investigator: Prof Sarah Fidler
Funder: Bill & Melinda Gates Foundation

POPPY Waves 4 & 5

A prospective, observational study to examine the effects of ageing on the clinical outcomes of people living with HIV in England and Ireland - Waves 4 and 5 POPPY 4 & 5 – ‘Pharmacokinetic and Clinical Observations in People over Fifty Waves 4 and 5

POPPY Waves 4 & 5 - Health Research Authority (hra.nhs.uk)

Principal investigator: Prof Alan Winston

DOLOMITE

A Cohort Study to assess DTG Safety in HIV Pregnant Women

DOLOMITE: A Cohort Study to assess DTG Safety in HIV Pregnant Women - Health Research Authority (hra.nhs.uk)

Principal investigator: Prof Graham Taylor

SEPAC

Screening and Early Detection to Prevent Anal Cancer; development of a biomarker screening tool

This study aims to develop and evaluate a primary screening tool for anal pre-cancer that would allow the identification and treatment of early disease, thus reduce the morbidity and mortality associated with anal cancer. We will recruit 1000 HIV-positive MSM aged 40 years or older from five participating HIV clinics across England. All participants will undergo HRA and have samples taken for biomarker analysis.

SEPAC - Health Research Authority (hra.nhs.uk)

Principal investigator: Dr John Walsh

Mistral

MISTRAL seeks to investigate how HIV infection and the gut microbiome interact. 

Mistral – Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications, antimicrobial drug resistance, and unresponsiveness to therapeutic HIV-1 vaccination (mistral-hiv.eu) 

Principal investigator: Prof Alan Winston

PRePaRe

To assess the use of PrEP among people newly diagnosed with HIV, to understand the circumstances under which these HIV infections occurred and to estimate the prevalence of HIV drug resistance in this group of people

HIV Pre-exposure prophylaxis and Resistance - PrEPaRe Version 1.0 - Health Research Authority (hra.nhs.uk)

Principal investigator: Dr Borja Mora-Peris

CASCADE

Qualitative observational study of the experiences and needs of people with recently acquired HIV

CASCADE study | Living with HIV ; CASCADE Study | Institute for Global Health - UCL – University College London 

Principal investigator: Prof Sarah Fidler

Sexual Health studies

UK Acute Cohort for Hepatitis C

UK Cohort for Acute Hepatitis C: A prospective, multicentre, observational, cohort study of Acute Hepatitis C in the United Kingdom

UK Acute Cohort for Hepatitis C - Health Research Authority (hra.nhs.uk)

Principal investigator: Prof Graham Cooke

COVID and other Infectious Diseases studies

PEARL

Prospective Cohort for Early Detection of Liver Cancer

Pearl - Health Research Authority (hra.nhs.uk)

Principal investigator: Dr Nowlan Selvapatt (hepatology team)
Departmental investigator: Prof Graham Cooke

SAGE

The immunogenicity of Shingrix vaccination in people living with HIV at risk of shingles infection.

SAGE - Health Research Authority (hra.nhs.uk)

Principal investigator: Prof Sarah Fidler